Preprint · CC-BY
via OpenAlex
Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial
Santosh Kumari, Matthew P. Bubak, Hayden M. Schoenberg, Arik Davidyan, Christian J. Elliehausen, Katrin Gaardbo Kuhn, Timothy M. VanWagoner, Rowan Karaman, Robert Hal Scofield, Benjamin F. Miller, Adam R. Konopka
medRxiv · 2021 · ▲ 2 citations
Abstract
Abstract The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan(definition) in humans. While there is extensive epidemiological support for the health benefits of metformin in patient populations, it is not clear if these protective effects apply to those free of age-related disease. Our previous data in older adults without diabetes suggest a dichotomous change in insulin sensitivity and skeletal muscle mitochondrial adaptations after metformin treatment when co-prescribed with exercise. Those who entered the study as insulin sensitive had no change to detrimental effects while those who were insulin resistant had positive changes. The objective of this clinical trial is to determine if 1) antecedent metabolic health and 2) skeletal muscle mitochondrial remodeling and function mediate the positive or detrimental effects of metformin monotherapy, independent of exercise, on the metabolism and biology of aging. In a randomized, double blind clinical trial, adults free of chronic disease (n=148, 40-75 years old) are stratified as either insulin sensitive or insulin resistant based on HOMA-IR (≤2.2 or ≥2.5) and take 1500 mg/day of metformin or placebo for 12 weeks. Hyperinsulinemic-euglycemic clamps and skeletal muscle biopsies are performed before and after 12 weeks to assess primary outcomes of peripheral insulin sensitivity and mitochondrial remodeling and function. Findings from this trial will identify clinical characteristics and cellular mechanisms involved in modulating the effectiveness of metformin treatment to target aging that could inform larger phase 3 clinical trials aimed at testing aging as an indication for metformin.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/2021.10.20.21265196
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Kumari, S., Bubak, M.P., Schoenberg, H.M., Davidyan, A., Elliehausen, C.J., Kuhn, K.G., VanWagoner, T.M., Karaman, R., Scofield, R.H., Miller, B.F., & Konopka, A.R. (2021). Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial. <em>medRxiv</em>. https://doi.org/10.1101/2021.10.20.21265196
Vancouver
Kumari S, Bubak MP, Schoenberg HM, Davidyan A, Elliehausen CJ, Kuhn KG, et al. Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial. medRxiv. 2021. doi:10.1101/2021.10.20.21265196.
BibTeX
@unpublished{santosh2021Antece,
title = {Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial},
author = {Santosh Kumari and Matthew P. Bubak and Hayden M. Schoenberg and Arik Davidyan and Christian J. Elliehausen and Katrin Gaardbo Kuhn and Timothy M. VanWagoner and Rowan Karaman and Robert Hal Scofield and Benjamin F. Miller and Adam R. Konopka},
journal = {medRxiv},
year = {2021},
doi = {10.1101/2021.10.20.21265196},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2021
Preprint · CC-BY
Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · OA
Metformin treatment results in distinctive skeletal muscle mitochondrial remodeling in rats with different intrinsic aerobic capacities
Aging Cell 2024
Open access · CC-BY
Metformin treatment results in distinctive skeletal muscle mitochondrial remodeling in rats with different intrinsic aerobic capacities
Aging Cell 2018
Open access · CC-BY
Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
CanSino Biologics Inc. 2020
Open access · US-GOV